Interesting article on Acadia from 22nd Dec 2021,
it mentions how important it is to get FDA approval for trofinetide in context to their overall drug pipeline.
whatever happens, 2022 will be a huge year for NEU.
https://www.**promotion blocked**/investing/2021/12/22/why-acadia-pharmaceuticals-climbed-more-than-10-we/
from article
Now whatWhile Nuplazid is the company's only marketed drug, it does have several other therapies in its pipeline, including trofinetide for Rett syndrome. The biotech company has already completed a phase 3 trial for trofinetide and says it plans to submit a New Drug Application in mid-2022. Acadia also has a two early-stage therapies, ACP-044, a non-opioid analgesic, and ACP-319, a drug designed to improve cognitive function and alleviate other neuropsychiatric symptoms associated with various central nervous system disorders. The company also is looking to expand Nuplazid's label as an anti-hallucination drug for schizophrenia patients.Looking at the company's financials, it's clear that it needs to expand Nuplazid's label or hope that trofinetide is approved. The company did report $131.6 million in revenue in the third quarter, all from Nuplazid, and up 9% year over year. The company has significantly tightened its belt, but it is still losing money. It reported a net loss of $14.5 million in the quarter, compared to a loss of $84.7 million in the same period last year. The company has time to become profitable, however, with enough cash ($540 million) to last more than eight years at the current burn rate.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$12.71 |
Change
-0.250(1.93%) |
Mkt cap ! $1.574B | |||
| Open | High | Low | Value | Volume |
| $12.82 | $13.05 | $12.53 | $5.101M | 398.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 15 | $12.71 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.72 | 150 | 2 |
View Market Depth
| Last trade - 15.34pm 17/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |